Vina Del Mar, V Region, Chile

Phase 3 Inhaled Novaferon Study in Hospitalized Patients With Moderate to Severe COVID-19

The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

Evaluation of the EEG Connectivity Using Predominant Dexmedetomidine as Anesthetic in Fragile Brains

Research question: Does subcortical drug-based anesthesia allow better recovery of consciousness (integration of information) than the classic gabaergic drug-based technique in elderly and fragile brains? Primary hypothesis: The anesthetic technique based on subcortical anesthesia with Dexmedetomidine and Remifentanil and minimal gabaergic doses (Propofol) allow fragile and slower brains a faster recovery of cortical connectivity. This behavior represents part of the evidence of neural inertia in sleep and anesthesia. Objectives: 1. Primary: Evaluation of the normalization of the frontal EEG of patients with mostly subcortical anesthesia (Dexmedetomidine-Remifentanil.-low Propofol in TCI ) or classic technique (Remifentanil-Propofol in TCI) versus its preoperative basal control. 2. Secondary: 1. To estimate the recovery of the cognitive condition with MoCA test, agitation scale, and delirium CAM-ICU. 2. To identify behavioral patterns of the EEG with two different anesthetic techniques Participants 1. Target population: Patients scheduled for elective surgery, any sex, non-neurological procedure lasting more than 60 minutes, who do not meet the exclusion criteria. 2. Eligibility criteria Inclusion criteria: - ASA I - II - Age: over 70 years old Exclusion criteria: - Neurological, or systemic disease that affects the central nervous system in a secondary way - Abnormal admission neurological physical exam - Consumption of benzodiazepines, tricyclic antidepressants, sympathomimetics, modafinil, opioid analgesics, histaminergic, antihistamines, cholinergic, anticholinergics, dopaminergic, antidopaminergic, and antihypertensive with alpha-agonist effect in the last 48 hours. - History of adverse or allergic reactions to Propofol (allergy to soy or any other component of it) - History of alcohol or drug abuse - Subjects with "fast sequence induction" indication Withdrawal criteria: - Patients presenting with any adverse event during induction (excitation, hypotension, bradycardia <40 x min, nausea). - Subsequent refusal to participate in the study 1. Randomize patients into two groups of a similar number of individuals. Group 1: Propofol TCI - Remifentanil anesthesia. TCI Propofol (Schnider PKPD model), 5-minute step-by-step induction. After LOC stay in this calculated effect site concentration, add Remifentanil TCI PKPD model Minto target 4.5 ng/ml, Rocuronium intubation dose. EEG Sedline monitoring all the surgery until 1 hour postoperatively Group 2: Dexmedetomidine 0.8 ug/kg/h during 10 minutes- then Propofol TCI target 2 ug/ml (Schnidel model) during 3 min and reduce to 0.5 ug/ml, Remifentanil TCI (PK model Minto), after LOC Rocuronium intubation dose. EEG Sedline monitoring all the surgery until 1 hour postoperatively 0,5 ug/ml after LOC 2. Both groups were evaluated with MoCA and CAMICU tests: Pre-operative and post-operative cognitive assessments will be performed with MoCA test and CAMICU test, which will be correlated with the EEG characteristics of each group both in the baseline measurements, intraoperative behavior, and after one hour in the recovery room 3. Basal frontal EEG with eyes opened and closed (90 sec each) preoperatively without any drug effect To protect the risk of awareness or excess of EEG depression, during surgery, Anesthesia will be dynamically adjusted to maintain SEF95 remains at minimum values at 8-10 Hz for the rest of the surgery. Sedline will be maintained for up to 60 min post-op. in the recovery room. Data will be retrieved via pen drive stick (edf data corresponding to raw EEG) and other trends data of the Sedlie monitor using the proprietary software Masimo Instrument Configuration Tools In both groups, the Systolic Blood Pressure, Freq. Cardiac, Pulse Oximetry, Capnography, and Sedline EEG will be monitored throughout the surgical procedure and for at least one hour postoperatively. No drugs such as ketamine, midazolam, atropine, or other anticholinergics will be used at any time. Hemodynamics will be supported with volume, ephedrine, or phenylephrine according to the criteria of the anesthesiologist. Unexpected events during the induction: Any anesthetic induction has risks of hemodynamic instability, arrhythmias, and respiratory apneas. Most of them are easy to handle anesthesiological based on volume, vasoactive drugs such as ephedrine, and respiratory assistance. In this case, a minimum or no incidence of these is expected because healthy patients are included. Exceptional situations such as anaphylactic reactions to propofol (very rarely described) will be cause for suspension of the case study and treated with usual protocols for the case. During the Surgery, the analgesic requirement will be adjusted with Remifentanil TCI concentration in the clinical criterium of the anesthetist. Postoperative analgesia will be multimodal, with or without regional block depending on the anesthetist's criterium and type of surgery. Database and data management: SEDLINE data is retrieved online by proprietary software to a PC. These, together with the manual control data, will be collected in a Microsoft Excel 2011 worksheet and exported to a STATA 10 statistical program template, with which the analysis will be performed. A work together with the Basic Data Manager of the Anesthesia Service to safeguard the information and its confidentiality.

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus

Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

Re-evaluation of the Effect Site Model of the PKPD Propofol Eleveld Model

Eleveld is a recently developed PKPD model of propofol, which includes multiple covariates in its pharmacokinetics. This model, called Universal, includes data from all studies conducted with plasma levels in the world, where the principal investigator (PSV) has been directly involved. For pharmacodynamics (PD), Eleveld, includes processed electroencephalogram (EEG) readings, but only by nominal BIS index. The use of BIS as a unique marker of propofol hypnosis shows multiple limitations as it results from a computer algorithmic application, which can be influenced by drugs, inter-individual variability, among others. Therefore, to determine the effect there are nowadays more accurate tools such as spectrogram processing and determination of alpha power by spectral density (PDS). This project aims to re-evaluate the modelling of the temporal behaviour of the effect in the BIS index, using the reference of the Eleveld kinetic model, associated to a spectrogram that allows the evaluation of the alpha and delta band dynamics as a predictor of the propofol effect. In our study we intend to replace the BIS value by the alpha and delta power progress in decibels (dB) and eventually build a pharmacodynamic (PD) model with a marker more associated to the specific cortical electrical phenomenon.

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Monotherapy Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis